The case for & against
Bull & Bear analysis
Agenus Inc. (NASDAQ: AGEN) is a biotechnology company that focuses on developing innovative immuno-oncology therapies to treat various cancers, specifically targeting treatment-resistant malignancies like colorectal cancer through its lead candidate, ButVal (botensilimab plus balstilimab). The company positions itself within the oncology sector, where there is significant unmet medical need, especially among younger patients facing rising colorectal cancer incidences. Agenus aims to leverage strategic partnerships and recent clinical advancements to enhance its operational capabilities and accelerate the path toward commercialization.
Bull says
- ↑23% overall response rate in MSS colorectal vs standard care
- ↑Zydus partnership yields $75M upfront and $50M in milestones
- ↑Preparing for FDA Type B meeting for accelerated approval
- ↑Annual cash burn cut from $224M to $50M
- ↑CRC incidence doubled in U.S. adults under 55
- ↑Dividend yield ~1.2% with moderate leverage risk
Bear says
- ↓Net loss of $232.3M in 2024 undermines financial stability
- ↓Needs external funding for Phase III trials despite cash burn
- ↓Annual cash burn ~ $50M risks liquidity without new capital
- ↓Negative growth momentum and earnings yield signal valuation risk
- ↓High stock volatility adds regulatory and market execution risk
- ↓Small market position with competitive pressures in CRC
Investment themes with AGEN
Genetic and drug innovations driving medical breakthroughs
Stocks with highest short interest
Earnings Call · Q1 2024 · Mgmt. Guidance
Transcript signals
Bull points
- The confirmed overall response rate in all patients treated is 23%, with a median overall survival of 21.2 months, a 12-month overall survival estimate of 71%, and an 18-month overall survival estimate of 62%. The most common safety observations are immune-related diarrhea and colitis, which is managed in accordance with standard therapies. Grade 3 or greater treatment-related diarrhea colitis occurred in approximately 16% of patients. These data, which continue to mature, stand in stark contrast to standard of care therapies in this treatment setting, with overall response rates of 1% to 6%, and a median overall survival of 12 months or less.
- In November 2023, we completed enrollment in a large randomized global phase two trial with 234 metastatic colorectal cancer patients whose tumors were not MSI high or DMMR and were without active liver metastasis.
- We look forward to submitting more mature results from this trial to a scientific meeting in the second half of 2024, supporting our anticipated BLA filing by the end of the year.
Bear points
- Our cash used in operations for this first quarter was $38 million compared to $40 million during the fourth quarter ended December 31, 2023.
- For the first quarter ended March 31, 2024, we recognized revenue of $28 million and incurred a net loss of $63.5 million, which includes non-cash expenses of $38 million. This compares to a net loss of $70.9 million, which includes non-cash expenses of $25 million for the same period in 2023.
- Our net loss per share for this first quarter is $3.04, which compares to $4.31 per share for the first quarter of 2023.